Obstet Gynecol. 2014 May;123 Suppl 1:67S. doi: 10.1097/01.AOG.0000447375.44931.c7.
Effect of commercial cell-free fetal DNA tests for aneuploidy screening on rates of invasive testing.
The objective of this study was to determine the effect of new commercial tests for aneuploidy screening using cell-free fetal DNA on rates of invasive testing.
Commercial aneuploidy screening tests using cell-free fetal DNA were first offered at Lehigh Valley Health Network Maternal Fetal Medicine in late December 2011. All patients offered cell-free fetal DNA testing were at high risk for fetal aneuploidy defined as advanced maternal age, abnormal aneuploidy screening, abnormal ultrasound findings, personal or family history, or all of these. Data regarding cell-free fetal DNA test rates, invasive testing rates (amniocentesis and chorionic villus sampling), and indication for testing were collected. Invasive testing indications were further categorized into testing for aneuploidy or for other indications. χ was used to compare rates of invasive testing before and after introduction of cell-free fetal DNA testing.
Three hundred sixty-five patients underwent cell-free fetal DNA testing from December 1, 2011 to December 30, 2012. The rates of invasive testing overall and invasive testing for aneuploidy both decreased significantly after introduction of cell-free fetal DNA testing as compared with before (P<.001). The difference in the number of invasive tests over time was the result of a decrease in procedures for aneuploidy testing (). The number of cell-free fetal DNA tests increased significantly from the first half of 2012 to the second half of 2012 (P<.001).(Figure is included in full-text article.)
: The new commercial tests available for aneuploidy screening using cell-free fetal DNA were rapidly incorporated into clinical practice and are associated with decreased use of invasive tests.
- [PubMed - in process]